SRPT Sarepta Therapeutics Inc

Price (delayed)

$84.19

Market cap

$6.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.03

Enterprise value

$6.18B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The revenue rose by 33% YoY and by 4.7% QoQ
SRPT's gross profit is up by 32% year-on-year and by 4.1% since the previous quarter
The net income has decreased by 20% YoY but it has increased by 10% QoQ
The EPS has contracted by 14% YoY but it has grown by 10% from the previous quarter
The company's equity has shrunk by 53% YoY and by 9% QoQ
SRPT's debt has surged by 51% year-on-year

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
79.84M
Market cap
$6.72B
Enterprise value
$6.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.84
Price to sales (P/S)
11.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.3
Earnings
Revenue
$600.08M
EBIT
-$634.04M
EBITDA
-$589.29M
Free cash flow
-$783.19M
Per share
EPS
-$8.03
Free cash flow per share
-$9.82
Book value per share
$6.08
Revenue per share
$7.52
TBVPS
$34.42
Balance sheet
Total assets
$2.76B
Total liabilities
$2.27B
Debt
$1.16B
Equity
$485.11M
Working capital
$1.84B
Liquidity
Debt to equity
2.39
Current ratio
5.33
Quick ratio
4.36
Net debt/EBITDA
0.91
Margins
EBITDA margin
-98.2%
Gross margin
86.8%
Net margin
-105.7%
Operating margin
-104.5%
Efficiency
Return on assets
-22.5%
Return on equity
-94.9%
Return on invested capital
-33.2%
Return on capital employed
-27.2%
Return on sales
-105.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
1.43%
1 week
-15.32%
1 month
0.17%
1 year
-41.26%
YTD
-50.62%
QTD
-8.96%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$600.08M
Gross profit
$520.8M
Operating income
-$627.22M
Net income
-$634.47M
Gross margin
86.8%
Net margin
-105.7%
The revenue rose by 33% YoY and by 4.7% QoQ
SRPT's gross profit is up by 32% year-on-year and by 4.1% since the previous quarter
SRPT's operating margin is up by 23% YoY
The net income has decreased by 20% YoY but it has increased by 10% QoQ

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
13.84
P/S
11.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.3
The EPS has contracted by 14% YoY but it has grown by 10% from the previous quarter
SRPT's P/B is 54% above its 5-year quarterly average of 9.0 and 2.5% above its last 4 quarters average of 13.5
The company's equity has shrunk by 53% YoY and by 9% QoQ
The P/S is 71% less than the 5-year quarterly average of 38.8 and 34% less than the last 4 quarters average of 16.9
The revenue rose by 33% YoY and by 4.7% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The return on equity has dropped by 79% year-on-year and by 9% since the previous quarter
The ROS has grown by 14% from the previous quarter and by 10% YoY
Sarepta Therapeutics's ROIC has increased by 11% from the previous quarter and by 7% YoY
The ROA has increased by 9% from the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 21% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 29% YoY and by 14% from the previous quarter
SRPT's total liabilities is up by 24% YoY
SRPT's debt is 139% greater than its equity
The company's equity has shrunk by 53% YoY and by 9% QoQ
SRPT's debt has surged by 51% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.